3Choi HJ,Sohn JH, Lee CG. A phase I study of nimotuzumab in combination with radical therapy:Korean results. Lung Cancer, 2010: 1342-1346.
4Lordick F ,Lorenzen S.Cetuximab and cisplatin/Sfu versus CF in firstline metastalic squamous cell carcinoma of the esophagus (MESCC):A randomized phase 1I study of the Arbeitsgeinschaf! Internistische Onkologie(AIO) .J Clin Oncol,ASCO 2008(abstr.4546).
5Richards DA, Kocs DM, Spira AI, et ah Results of docetaxel plus oxaliplatin (DOCOX) with or without cetuximab in patients with metastatric and/or gastroesophagel junction adenocm'cin- ma:Results of a randomized phase 1I study.J Clin Oncol, 2011, 29:4015-4023.
6Vickers, MM Powell ED, Asmis TR, e~ al.Comorbidity and overall survival (OS) in patients with advanced pancreatic cancer (APC) : results from NCLC CTG PA3-A phase m trial of erlotinib plus gemcitabine (EG) versus gemcitabine (G) alone.J Clin Oncol ,2010, 28: 4079-4089.
7Ciardiello F ,Tortora G. EGFR antagonists in cancer treatment.New Engl J Med, 2008, 358:1160-1169.
8Lam C, Bouffet E, Barrel U. Nimotuzumab in pediatric glioma. Future Onco1,2009, 5:1349-1356.
9Cromber T, Osiorio M, Cruz T, et al. Use of the humanized anti- Epidermal Growth Factor Receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol, 2004, 22:1646-1649.
10Ramakrishnan MS, Eswariah A, Cromber T, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial. MABs, 2009, 1:41-48.
